How do amphotericin B and flucytosine work synergistically to treat a CNS fungal infection such as a dural abscess?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Synergistic Mechanism of Amphotericin B and Flucytosine in CNS Fungal Infections

Amphotericin B and flucytosine work synergistically through complementary mechanisms: amphotericin B disrupts fungal cell membranes creating pores that enhance flucytosine uptake, while flucytosine inhibits fungal DNA/RNA synthesis once inside the cell, resulting in superior fungicidal activity compared to either agent alone. 1, 2

Mechanism of Action

Amphotericin B's Role

Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that increase membrane permeability. This disruption serves two critical functions:

  • Direct fungicidal activity through membrane destabilization
  • Enhanced cellular uptake of flucytosine by compromising membrane integrity 2

Flucytosine's Role

Flucytosine enters fungal cells via cytosine permease and undergoes intracellular conversion:

  • Converted to fluorouracil by cytosine deaminase
  • Fluorouracil metabolites falsely incorporate into fungal RNA (inhibiting protein synthesis)
  • Inhibits thymidylate synthetase (blocking DNA biosynthesis) 2

The Synergistic Effect

The combination achieves superior outcomes because amphotericin B's membrane disruption significantly increases flucytosine penetration into fungal cells, while flucytosine's excellent CSF penetration compensates for amphotericin B's more limited CNS distribution. 1, 3

Clinical Evidence for CNS Infections

Demonstrated Benefits

For CNS candidiasis and cryptococcosis, the combination demonstrates:

  • In vitro synergism against Candida and Cryptococcus species 1
  • Enhanced fungal clearance: -0.42 log10 CFU/mL/day with combination vs. -0.31 log10 CFU/mL/day with amphotericin B alone 4
  • Improved survival: 44% reduction in 2-week mortality (RR 0.56,95% CI 0.33-0.95) for cryptococcal meningitis 5
  • Faster CSF sterilization in CNS infections 1, 6

Pharmacokinetic Advantages

The combination exploits complementary drug distribution:

  • Flucytosine achieves excellent CSF concentrations (approaching serum levels)
  • Liposomal amphotericin B attains higher brain tissue levels than conventional formulations 1
  • Non-overlapping toxicity profiles allow full dosing of both agents 7

Recommended Regimen for CNS Fungal Infections

For CNS candidiasis (including dural abscess):

  • Liposomal amphotericin B 5 mg/kg IV daily PLUS
  • Flucytosine 25 mg/kg PO four times daily 1
  • Duration: Several weeks until clinical/CSF improvement, then transition to fluconazole 1

For cryptococcal meningitis:

  • Amphotericin B deoxycholate 0.7-1 mg/kg IV daily (or liposomal formulation 3-5 mg/kg) PLUS
  • Flucytosine 100 mg/kg/day divided in 4 doses 8, 9
  • Duration: Minimum 2 weeks induction therapy 8, 10

Critical Monitoring Requirements

Flucytosine requires intensive monitoring due to significant toxicity risks:

  • Serum flucytosine levels frequently (target 40-60 μg/mL) 11
  • Complete blood counts (bone marrow suppression risk)
  • Liver function tests (hepatotoxicity)
  • Renal function (dose adjustment needed) 1, 11

Common Pitfall

Never use flucytosine as monotherapy—resistance develops rapidly during single-agent treatment. The combination with amphotericin B prevents resistance emergence while maximizing fungicidal activity. 2

When Flucytosine is Unavailable or Contraindicated

If flucytosine cannot be used:

  • Amphotericin B alone for 4-6 weeks, OR
  • Amphotericin B plus high-dose fluconazole 800 mg daily 1

However, these alternatives show inferior fungal clearance rates and should only be used when the combination is not feasible 1.

References

Research

Combination antifungal therapy for cryptococcal meningitis.

The New England journal of medicine, 2013

Research

Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.